Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calistoga Pharmaceuticals, a developer of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, has appointed Clifford Stocks as its new chief business officer.
Subscribe to our email newsletter
Mr Stocks brings substantial experience and expertise to lead Calistoga Pharmaceuticals’s business and corporate development strategy, and business practices. Mr Stocks will be responsible for corporate/business development, finance and legal.
Mr Stocks brings to Calistoga Pharmaceuticals more than two decades of experience in the biotech industry, including 15 years at Icos, where he served as an executive officer and vice president of business development.
Mr Stocks also serves on the board of Sinova Pharmaceuticals, a biotech startup in Shanghai, China. Mr Stocks has received an MBA from the University of Chicago Graduate School of Business, and a BS degree in biology from the University of Utah.
Carol Gallagher, CEO of Calistoga, said: “Cliff is an accomplished, skilled executive with extensive experience in corporate strategy and a wide range of business development activities. He will be a valuable addition to our team as we advance our clinical compounds and assess strategic partnership opportunities.”